|
|
Bibliopsiquis >
Áreas Temáticas >
Esquizofrenia y otras Psicosis >
Por favor, use este identificador para citar o enlazar este registro:
http://hdl.handle.net/10401/1490
|
| Título: | A flexible-dose study of Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with Aripiprazole. |
| Autor: | Schreiner, A.
Hoeben, D.
Lahaye, M.
Tessier, C.
Naber, D.
Peuskens, J.
Vauth, R.
Jasovic-Gasic, M.
Rancans, E.
Didi, R. |
| Fecha: | jun-2010 |
| Tipo de documento: | Comunicación congreso |
| Resumen: | *Among non-acute patients with schizophrenia
transitioned to paliperidone ER for the main reason of lack of efficacy with previous aripiprazole treatment,more than 58% had an improvement in PANSS total scores of ≥ 20% from baseline to endpoint.
*Among patients switching to paliperidone ER from aripiprazole for main reasons of lack of tolerability and reasons other than lack of efficacy, tolerability, or compliance, PANSS total scores at endpoint met prespecified non-inferiority criteria.
*For all patients, PANSS total score from baseline to endpoint improved significantly (P < 0.0001).
*Clinically relevant and statistically significant improvements occurred in PANSS total, subscale, and Marder factor scores (P < 0.05), with significant improvements in PANSS total scores noted from the first post-baseline assessment (4 weeks after initiating paliperidone ER).
*The percentage of patients with severe or varying degrees of functional impairment decreased from 91% at baseline to 72% at endpoint.
*Patient satisfaction, an important predictor for adherence to treatment, was good or very good in 18% of patients previously unsuccessfully treated with
aripiprazole. Patient satisfaction after treatment with paliperidone ER was good or very good in 57% of patients.
*TEAEs occurring in ≥ 5% of patients were anxiety (7.8%), insomnia (7.8%), somnolence (7.1%), weight increase (6.4%), and akathisia (5.0%).
*ESRS scores decreased (i.e. improved) statistically significantly from 3.2 ± 4.5 to 2.3 ± 4.3 (P = 0.0004). This statistically significant, while numerically small,improvement may be clinically relevant as aripiprazole is generally considered to be well tolerated.
*Mean body weight change from baseline to endpoint after switching to paliperidone ER was only 0.6 ± 4.7 kg.
*Flexibly dosed paliperidone ER treatment over 6 months was safe, well tolerated, and associated with meaningful treatment response in patients previously
unsuccessfully treated with aripiprazole. |
| Descripción: | Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010. |
| URL persistente: | http://hdl.handle.net/10401/1490 |
| Aparece en las colecciones: | Esquizofrenia y otras Psicosis
|
Ficheros en este registro:
|
Los registros de Bibliopsiquis están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.
|
